JMP Securities reiterated coverage on Seagen with a new price target
$SGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JMP Securities reiterated coverage of Seagen with a rating of Market Outperform and set a new price target of $142.00 from $201.00 previously